Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Therapy for Pediatric Hodgkin's Disease
NCT00145600Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2000
- Primary completion
- May 2012
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of 6-mercaptopurine + methotrexate + prednisolone + vincristine, Creatinolfosfate and Stanford V in Hodgkin lymphoma (HL) (4 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Event-free Survival Probability. Started Mar 2000; status: completed.
02
Drugs
6-mercaptopurine + methotrexate + prednisolone + vincristineCreatinolfosfateStanford V
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00145600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145600.